Not logged in Share Save
Share Save
Share Save
OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103) Tolaney, Sara; Ballman, Karla; Perou, Charles M.; Cescon, David; Gatti-Mays, Margaret; Blinder, Victoria; Rosenberg, Shoshana; Mittendorf, Elizabeth; Weiss, Anna; Rugo, Hope; Ho, Alice; Casey, Dana; Singh, Baljit; Smieliauskas, Fabrice; Abdou, Yara; Damarla, Vijay; Meisel, Jane; Carey, Lisa; Partridge, Ann Share Save
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials Rediti, Mattia; Fernandez-Martinez, Aranzazu; Venet, David; Rothe, Francoise; Hoadley, Katherine A.; Parker, Joel S.; Singh, Baljit; Campbell, Jordan D.; Ballman, Karla V.; Hillman, David W.; Winer, Eric P.; El-Abed, Sarra; Piccart, Martine; Di Cosimo, Serena; Symmans, William Fraser; Krop, Ian E.; Salgado, Roberto; Loi, Sherene; Pusztai, Lajos; Perou, Charles M.; Carey, Lisa A.; Sotiriou, Christos Share Save
Share Save
Share Save
Preclinical evaluation of ADVM-062, a novel intravitreal gene therapy vector for the treatment of blue cone monochromacy Hanna, Kelly; Nieves, Julio; Dowd, Christine; Bender, Kristina Oresic; Sharma, Pallavi; Singh, Baljit; Renz, Mark; Hoeve, James N. Ver; Cepeda, Diana; Gelfman, Claire M.; Riley, Brigit E.; Grishanin, Ruslan N. Share Save
Share Save
Share Save
Share Save
Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials Fernandez-Martinez, A.; Pascual, T.; Singh, B.; Nuciforo, P.; Hoadley, K. A.; Rashid, N. U.; Spears, P. A.; Chic, N.; Krop, I.; Hillman, D.; Partridge, A.; Prat, A.; Carey, L. A.; Perou, C. M. Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save